Asia One3h
Singapore company sued by Novo Nordisk over $1.7b hypertension drug deal
Novo Nordisk is seeking up to US$830 million (S$1.1 billion) in damages from KBP Biosciences, according to a ruling by a ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Channel NewsAsia Singapore10h
Novo Nordisk alleges fraud after US$1.3 billion deal to buy hypertension drug from Singapore-based KBP Biosciences
Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...